[A26-04] Toripalimab (nasopharyngeal carcinoma) – Benefit assessment according to §35a Social Code Book V
Last updated 15.04.2026
Project no.:
A26-04
Commission:
Commission awarded on 15.01.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (NPC) in first-line treatment
Result of dossier assessment:
- Patients with metastatic NPC: added benefit not proven
- Patients with recurrent NPC: hint of considerable added benefit
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A26-04
| Project no. | Title | Status |
|---|---|---|
| A26-05 | Toripalimab (oesophageal carcinoma) – Benefit assessment according to §35a Social Code Book V | Commission completed |